Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.
Urbonas V. et al, (2018), Annals of oncology : official journal of the European Society for Medical Oncology
Phase II trial Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
MIDDLETON MR. et al, (2018), Annals of Oncology
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238)
Weber JS. et al, (2018), BRITISH JOURNAL OF CANCER, 119, 41 - 42
VCAM-1 targeted magnetic resonance imaging enables detection of brain micrometastases from different primary tumours
CHENG VWT. et al, (2018), Clinical Cancer Research
A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours
Wilson R. et al, (2018), EUROPEAN JOURNAL OF CANCER, 103, E140 - E141
Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?
Middleton MR., (2018), Lancet Oncol, 19, 1424 - 1426
Single cell RNA-seq reveals profound transcriptional similarity between Barrett’s oesophagus and oesophageal submucosal glands
LU X. et al, (2018), Nature Communications
A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM).
Corrie PG. et al, (2018), Ann Oncol, 29 Suppl 8
Systematic review of patient-reported outcome measures used in randomised clinical trials testing checkpoint inhibitor immunotherapy for cancer
Peters M. et al, (2018), QUALITY OF LIFE RESEARCH, 27, S117 - S118
Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.
Lyon PC. et al, (2018), The Lancet. Oncology, 19, 1027 - 1039
25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
Lipplaa A. et al, (2018), British Journal of Cancer
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG. et al, (2018), Annals of oncology : official journal of the European Society for Medical Oncology
A decision support system for the treatment of esophageal cancer
Mistry H. et al, (2018), CANCER RESEARCH, 78
INCIDENCE AND MANAGEMENT OF IMMUNOTHERAPY-INDUCED COLITIS IN A TERTIARY IBD CENTRE - CLINICAL PRACTICE DATA
Gupta T. et al, (2018), GUT, 67, A186 - A187
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L. et al, (2018), BMC Health Serv Res, 18
First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors.
Azaro A. et al, (2018), JOURNAL OF CLINICAL ONCOLOGY, 36
Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma.
Shoushtari AN. et al, (2018), Journal of Clinical Oncology, 36, 9593 - 9593
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.
MacGregor TP. et al, (2018), Scientific reports, 8, 7265 - 7265